A pioneer in genetic analysis, Affymetrix introduced highly parallel genetic assays to the marketplace by commercializing the first DNA microarray in the late 1980s. Today researchers around the world use Affymetrix technologies to better understand the role that genes play in disease, the effectiveness and safety of therapies, and many other biological factors that affect human well-being.
“Illumina has been a member of ALSSA since shortly after the company was founded in 1998. As we have grown in a market where technologies are rapidly evolving, we have found the ALSSA meetings and the many opportunities for dialogue with other companies and senior executives to be an invaluable benefit of the association.”